BSE Live
Mar 27, 16:01Prev. Close
1243.90
Open Price
1237.35
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:58Prev. Close
1244.40
Open Price
1226.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1242.30 (203)
| Key Financial Ratios of Cipla (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 63.87 | 50.51 | 31.15 | 36.67 | 30.61 | |
| Diluted EPS (Rs.) | 63.82 | 50.46 | 31.12 | 36.63 | 30.57 | |
| Cash EPS (Rs.) | 70.97 | 57.78 | 38.52 | 42.36 | 37.50 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 397.46 | 346.49 | 305.25 | 279.05 | 247.10 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 397.46 | 346.49 | 305.25 | 279.05 | 247.10 | |
| Dividend / Share(Rs.) | 16.00 | 13.00 | 8.50 | 5.00 | 5.00 | |
| Revenue from Operations/Share (Rs.) | 235.82 | 205.29 | 195.63 | 162.27 | 172.37 | |
| PBDIT/Share (Rs.) | 83.74 | 68.80 | 52.65 | 49.99 | 49.00 | |
| PBIT/Share (Rs.) | 76.64 | 61.52 | 45.26 | 44.29 | 42.11 | |
| PBT/Share (Rs.) | 80.10 | 61.27 | 42.63 | 43.95 | 41.55 | |
| Net Profit/Share (Rs.) | 63.86 | 50.50 | 31.14 | 36.66 | 30.61 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 35.51 | 33.51 | 26.91 | 30.80 | 28.42 | |
| PBIT Margin (%) | 32.49 | 29.96 | 23.13 | 27.29 | 24.42 | |
| PBT Margin (%) | 33.96 | 29.84 | 21.78 | 27.08 | 24.10 | |
| Net Profit Margin (%) | 27.08 | 24.59 | 15.91 | 22.59 | 17.75 | |
| Return on Networth / Equity (%) | 16.06 | 14.57 | 10.20 | 13.13 | 12.38 | |
| Return on Capital Employed (%) | 19.11 | 17.61 | 14.67 | 15.72 | 16.75 | |
| Return on Assets (%) | 14.50 | 13.12 | 9.10 | 11.62 | 10.74 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 0.57 | 0.57 | 0.60 | 0.54 | 60.53 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 5.78 | 5.21 | 4.95 | 4.41 | 3.79 | |
| Quick Ratio (X) | 4.65 | 4.07 | 3.74 | 3.23 | 2.64 | |
| Inventory Turnover Ratio (X) | 5.55 | 0.80 | 1.08 | 0.88 | 4.50 | |
| Dividend Payout Ratio (NP) (%) | 20.35 | 16.82 | 16.05 | 13.63 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 18.31 | 14.70 | 12.97 | 11.80 | 0.00 | |
| Earnings Retention Ratio (%) | 79.65 | 83.18 | 83.95 | 86.37 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 81.69 | 85.30 | 87.03 | 88.20 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 116,153.24 | 120,337.37 | 71,729.50 | 80,744.55 | 64,871.04 | |
| EV/Net Operating Revenue (X) | 6.10 | 7.26 | 4.54 | 6.17 | 4.67 | |
| EV/EBITDA (X) | 17.17 | 21.66 | 16.88 | 20.02 | 16.42 | |
| MarketCap/Net Operating Revenue (X) | 6.11 | 7.28 | 4.60 | 6.28 | 4.73 | |
| Retention Ratios (%) | 79.64 | 83.17 | 83.94 | 86.36 | 0.00 | |
| Price/BV (X) | 3.63 | 4.31 | 2.95 | 3.65 | 3.30 | |
| Price/Net Operating Revenue | 6.11 | 7.28 | 4.60 | 6.28 | 4.73 | |
| Earnings Yield | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 |
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
23.02.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth